Table 3.
Associations between number of mutated genes and outcomes in patients with HGSOC.
| Median Survival | Univariate | Multivariate # | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of Patients | Time (Months) | HR * | 95% CI * | p * | HR * | 95% CI * | p * | |
| PFI a | ||||||||
| N. of mutated genes | ||||||||
| 0 | 12 | 18.5 | Ref. | - | - | Ref. | - | - |
| 1 | 44 | 8.6 | 1.23 | 0.62–2.43 | 0.559 | 1.35 | 0.63–2.87 | 0.439 |
| >1 | 7 | 8.1 | 2.55 | 1.10–5.92 | 0.029 | 3.10 | 1.13–8.48 | 0.028 |
| TTR a | ||||||||
| N. of mutated genes | ||||||||
| 0 | 12 | 24.2 | Ref. | - | - | Ref. | - | - |
| 1 | 44 | 14.4 | 1.18 | 0.57–2.43 | 0.656 | 1.29 | 0.59–2.85 | 0.523 |
| >1 | 7 | 13.5 | 2.57 | 1.07–6.19 | 0.035 | 3.14 | 1.13–8.74 | 0.028 |
| OS | ||||||||
| N. of mutated genes | ||||||||
| 0 | 12 | 66.0 | Ref. | - | - | Ref. | - | - |
| 1 | 45 | 47.7 | 1.31 | 0.47–3.64 | 0.597 | 1.47 | 0.51–4.23 | 0.469 |
| >1 | 7 | 34.0 | 2.58 | 0.91–7.34 | 0.076 | 3.40 | 1.14–10.12 | 0.028 |
| PFI a | ||||||||
| N. of mutated genes | ||||||||
| 0 or 1 b | 56 | 9.0 | Ref. | - | - | Ref. | - | - |
| >1 | 7 | 8.1 | 2.17 | 1.14–4.11 | 0.018 | 2.44 | 1.19–4.99 | 0.015 |
| TTR a | ||||||||
| N. of mutated genes | ||||||||
| 0 or 1 b | 56 | 14.9 | Ref. | - | - | Ref. | - | - |
| >1 | 7 | 13.5 | 2.25 | 1.19–4.26 | 0.012 | 2.54 | 1.27–5.09 | 0.008 |
| OS | ||||||||
| N. of mutated genes | ||||||||
| 0 or 1 b | 57 | 48.8 | Ref. | - | - | Ref. | - | - |
| >1 | 7 | 34.0 | 2.06 | 1.19–3.56 | 0.009 | 2.47 | 1.50–4.07 | <0.001 |
* Estimated through Cox proportional hazard model; # Adjusted for residual tumor after PDS, FIGO stage and age at diagnosis. a One patient was not evaluated due to loss at follow up. b Patients without (0) mutated genes and with only 1 mutated gene within the panel were grouped. Ref.: Reference Category; PFI: platinum free interval; TTR: time to recurrence; OS: overall survival. p values <0.05 were considered significant and were depicted in bold.